AC Immune SA

NASDAQ:ACIU   3:59:40 PM EDT
6.19
+0.01 (+0.16%)
Products, Regulatory, Earnings Announcements

AC Immune Reports Top Line Results From Tauriel Phase 2 Trial Evaluating Semorinemab In Early Alzheimer’s Disease

Published: 09/23/2020 11:21 GMT
AC Immune SA (ACIU) - Ac Immune Reports Top Line Results From Tauriel Phase 2 Trial Evaluating Semorinemab in Early Alzheimer’s Disease.
Ac Immune Sa - Genentech Disclosed Anti-tau Antibody Did Not Meet the Co-primary Efficacy Endpoint Or Two Secondary Endpoints in the Tauriel Study.
Ac Immune Sa - Investigational New Drug (ind) Enabling Studies Ongoing for First-in-class Therapeutic Candidates Targeting Tdp-43 and Alpha-synuclein.
Ac Immune Sa - Genentech, Informed Co of Study Results Which Show That Semorinemab Did Not Meet Its Primary Efficacy Endpoint.
Ac Immune Sa - Ac Immune Remains in a Strong Financial Position With Operations Fully Financed Through Q1 2024.
Revenue is expected to be $1.57 Million
Adjusted EPS is expected to be -$0.27

Next Quarter Revenue Guidance is expected to be $1.67 Million
Next Quarter EPS Guidance is expected to be -$0.29

More details on our Analysts Page.